In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advice From Investors On Early-Stage Financing

Startup financing may be hard to come by, but now is not the time to ask for less cash. 

Bayer’s BD And Licensing Strategy Key To Moving Through Difficult Period

As Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience

Data Spotlight

Weighty Matters: The Obesity Market Now… And In Years To Come

INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.

The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest

Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.

Private Equity And VC Fund Data: What Do The Numbers Show?

In Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.

Deals Of The Year 2023 Winners Revealed

For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

See All
Growth

Advice From Investors On Early-Stage Financing

Startup financing may be hard to come by, but now is not the time to ask for less cash. 

The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest

Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.

Private Equity And VC Fund Data: What Do The Numbers Show?

In Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.

The Biopharma A List: Taking The Pulse Of Newco Creation

On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.

See All
Innovation

Weighty Matters: The Obesity Market Now… And In Years To Come

INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.

First TIL Cell Therapy Approval Paves Way For Next Generation

Iovance Biotherapeutics' Amtagvi (lifileucel) received approval from the US FDA in February, marking a truly pivotal milestone in the field of solid tumor therapy for certain adult patients with unresectable or metastatic melanoma. As the first approved tumor infiltrating lymphocyte (TIL) therapy, it is set to expedite the regulatory pathway for next-generation products.

CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

What Big Pharmas Are Looking For In Partners

With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.

See All
Leadership

Bayer’s BD And Licensing Strategy Key To Moving Through Difficult Period

As Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience

Philips Doubles Down On ESG And AI While Servicing Respironics Recall Priority

Royal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.

Roche's Partnership Playbook: A Closer Look At 2023's Successes And 2024's Prospects

After chasing late-stage assets in 2023, Roche is moving back to its more diverse dealmaking approach. The company’s global head of pharma partnering, James Sabry, spoke to In Vivo about the value of partnerships at Roche and the formula for a successful collaboration. 

Immortalizing Janet Woodcock

Offering a regulatory Mt. Rushmore to place the outgoing principal deputy commissioner in historical context.

See All
Market Access

COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis

A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.

FTC’s Salvos Against Biopharma To Reverberate Through 2024

The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.

2024 Radar: UK Medtechs Up The Pace On Sustainability And Assess AI Potential

Three UK medtech companies’ views on how their businesses will be influenced by external factors in the coming year.

Times Of Unprecedented Change: German Medtech Readies For Challenging 2024

German medtech and health care are going through a period of unprecedented change and modernization, with hospital reform on the agenda and integration of digitized functionality happening across the sector. The EU Medical Device Regulation casts a long shadow over the medtech industry and will result in a shake out among companies and products, as In Vivo learnt at Medica 2023.

See All
Market Intelligence

AI Uses During Lifecycle Of Medicinal Products And Medical Devices: An EU Regulatory Perspective

Despite expectations in some circles in December 2023 that adoption of the EU AI Act was imminent, the scope of the final text and when it will be published remain unclear. There are, however, related consequences that can be anticipated. 

What Big Pharmas Are Looking For In Partners

With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.

Deals Of The Year 2023 Winners Revealed

For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

Fewer Acquisitions And Alliances In 2023, But Valuations Increased

INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.

See All
Recent Stories

COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis

A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.

AI Uses During Lifecycle Of Medicinal Products And Medical Devices: An EU Regulatory Perspective

Despite expectations in some circles in December 2023 that adoption of the EU AI Act was imminent, the scope of the final text and when it will be published remain unclear. There are, however, related consequences that can be anticipated. 

Weighty Matters: The Obesity Market Now… And In Years To Come

INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.

The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest

Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.

First TIL Cell Therapy Approval Paves Way For Next Generation

Iovance Biotherapeutics' Amtagvi (lifileucel) received approval from the US FDA in February, marking a truly pivotal milestone in the field of solid tumor therapy for certain adult patients with unresectable or metastatic melanoma. As the first approved tumor infiltrating lymphocyte (TIL) therapy, it is set to expedite the regulatory pathway for next-generation products.

Private Equity And VC Fund Data: What Do The Numbers Show?

In Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.

CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

The Biopharma A List: Taking The Pulse Of Newco Creation

On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.

What Big Pharmas Are Looking For In Partners

With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.

Deals Of The Year 2023 Winners Revealed

For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

Fewer Acquisitions And Alliances In 2023, But Valuations Increased

INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.

FTC’s Salvos Against Biopharma To Reverberate Through 2024

The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.

UsernamePublicRestriction

Register